KR20210018423A - 조직 석회화의 예방 또는 치료를 위한 방법 및 조성물 - Google Patents

조직 석회화의 예방 또는 치료를 위한 방법 및 조성물 Download PDF

Info

Publication number
KR20210018423A
KR20210018423A KR1020217000120A KR20217000120A KR20210018423A KR 20210018423 A KR20210018423 A KR 20210018423A KR 1020217000120 A KR1020217000120 A KR 1020217000120A KR 20217000120 A KR20217000120 A KR 20217000120A KR 20210018423 A KR20210018423 A KR 20210018423A
Authority
KR
South Korea
Prior art keywords
subject
mkh2
administration
protein
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217000120A
Other languages
English (en)
Korean (ko)
Inventor
제임스 에이 툼린
폴 엘 다크
존 엠 루디
Original Assignee
에피존 파마 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에피존 파마 인코포레이티드 filed Critical 에피존 파마 인코포레이티드
Publication of KR20210018423A publication Critical patent/KR20210018423A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217000120A 2018-06-08 2019-06-07 조직 석회화의 예방 또는 치료를 위한 방법 및 조성물 Ceased KR20210018423A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862682796P 2018-06-08 2018-06-08
US62/682,796 2018-06-08
PCT/US2019/036138 WO2019237053A1 (en) 2018-06-08 2019-06-07 Methods and compositions for preventing or treating tissue calcification

Publications (1)

Publication Number Publication Date
KR20210018423A true KR20210018423A (ko) 2021-02-17

Family

ID=68765387

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217000120A Ceased KR20210018423A (ko) 2018-06-08 2019-06-07 조직 석회화의 예방 또는 치료를 위한 방법 및 조성물

Country Status (11)

Country Link
US (8) US10688064B2 (https=)
EP (1) EP3801477A4 (https=)
JP (2) JP2021527128A (https=)
KR (1) KR20210018423A (https=)
CN (1) CN113038940A (https=)
AU (1) AU2019282420B2 (https=)
CA (1) CA3102977A1 (https=)
IL (1) IL279245B2 (https=)
MX (2) MX2020013302A (https=)
SG (1) SG11202012070YA (https=)
WO (1) WO2019237053A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024071848A1 (ko) * 2022-09-27 2024-04-04 경북대학교 산학협력단 혈관석회화 치료제 스크리닝 방법
WO2025075468A1 (ko) * 2023-10-06 2025-04-10 주식회사 레드엔비아 혈관 또는 판막 협착증의 예방 또는 치료용 병용제제

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019237054A1 (en) 2018-06-08 2019-12-12 Epizon Pharma, Inc. Methods and compositions for preventing or treating calciphylaxis
MX2020013302A (es) 2018-06-08 2021-05-12 Epizon Pharma Inc Métodos y composiciones para prevenir o tratar calcificación de tejido.
US10822295B2 (en) * 2018-09-12 2020-11-03 Epizon Pharma, Inc. Menaquinol compositions and methods of treatment
US20220160652A1 (en) * 2019-03-12 2022-05-26 Kaydence Pharma As Use of vitamin k in combination with anticoagulants
EP4367131A1 (en) * 2021-07-05 2024-05-15 Universiteit Maastricht Means and methods for the treatment of calcium crystal deposition diseases
WO2023129413A1 (en) * 2021-12-31 2023-07-06 Ingredient Fusion, Llc Molecular complexing method, formulation and manufacturing for enhanced nutrient delivery

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176778A1 (en) * 2001-08-03 2005-08-11 Vitak Bv Isoprenyl derivatives and their use in the title treatment and prevention of osteoporosis and cardiovascular calcification
WO2005030190A1 (en) * 2003-09-26 2005-04-07 Natural Asa Natural menaquinone 7 compositions
DE602006020658D1 (de) 2005-06-03 2011-04-28 Nattopharma Asa Verwendung von Vitamin K, um die Verkalkung der Blutgefässe rückgängig zu machen
NZ574882A (en) 2006-07-14 2012-08-31 Nattopharma Asa Pharmaceutical and nutraceutical products comprising vitamin k2
GB0817528D0 (en) 2008-09-24 2008-10-29 Syntavit As Process
BR112013009724A2 (pt) * 2010-11-01 2016-07-19 Viridis Biopharma Pvt Ltd equilíbrio dinâmico do sistemna nervoso autonômo utilizando a vitamina mk-7
GB201203705D0 (en) 2012-03-02 2012-04-18 Kappa Bioscience As Prodrugs
US10159787B2 (en) 2012-06-18 2018-12-25 Fresenius Kabi Deutschland Gmbh Port cannula system for puncturing port catheters
WO2014191466A1 (en) * 2013-05-28 2014-12-04 Nattopharma Asa Menaquinone supplementation and vascular health
GB201314245D0 (en) 2013-08-08 2013-09-25 Kappa Bioscience As Provitamins
EP3258924A2 (en) * 2015-02-20 2017-12-27 VitaK B.V. Vitamin k and capillary function
BR112017019750A2 (en) 2015-03-20 2018-05-29 Gnosis S.P.A. process for preparing a crystalline form of menaquinol, crystalline form of menaquinol, process for preparing a solid form of menaquinol, pharmaceutical or nutraceutical composition and use of the crystalline form of menaquinol
IT201700085412A1 (it) 2017-07-26 2019-01-26 Pharmanutra S P A Composizione per uso nella prevenzione e nel trattamento di patologie dell'apparato cardiovascolare
US10368858B1 (en) 2018-01-25 2019-08-06 Ring Orthopedics, Inc. Suture passer
WO2019237054A1 (en) 2018-06-08 2019-12-12 Epizon Pharma, Inc. Methods and compositions for preventing or treating calciphylaxis
MX2020013302A (es) 2018-06-08 2021-05-12 Epizon Pharma Inc Métodos y composiciones para prevenir o tratar calcificación de tejido.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024071848A1 (ko) * 2022-09-27 2024-04-04 경북대학교 산학협력단 혈관석회화 치료제 스크리닝 방법
WO2025075468A1 (ko) * 2023-10-06 2025-04-10 주식회사 레드엔비아 혈관 또는 판막 협착증의 예방 또는 치료용 병용제제

Also Published As

Publication number Publication date
MX2024013515A (es) 2024-12-06
WO2019237053A1 (en) 2019-12-12
JP2021527128A (ja) 2021-10-11
JP7847880B2 (ja) 2026-04-20
IL279245B1 (en) 2023-11-01
CA3102977A1 (en) 2019-12-12
US10744101B2 (en) 2020-08-18
US12377060B2 (en) 2025-08-05
US20210093584A1 (en) 2021-04-01
EP3801477A1 (en) 2021-04-14
US20250302772A1 (en) 2025-10-02
MX2020013302A (es) 2021-05-12
US20200222337A1 (en) 2020-07-16
SG11202012070YA (en) 2021-01-28
AU2019282420A1 (en) 2021-01-07
US11033515B2 (en) 2021-06-15
CN113038940A (zh) 2021-06-25
US20210378986A1 (en) 2021-12-09
IL279245A (en) 2021-01-31
US10688064B2 (en) 2020-06-23
US10874623B2 (en) 2020-12-29
US10744102B2 (en) 2020-08-18
US20190374484A1 (en) 2019-12-12
IL279245B2 (en) 2024-03-01
JP2024073612A (ja) 2024-05-29
EP3801477A4 (en) 2022-02-23
US20200206158A1 (en) 2020-07-02
AU2019282420B2 (en) 2025-03-20
US20240009144A1 (en) 2024-01-11
US11723882B2 (en) 2023-08-15
US20200206159A1 (en) 2020-07-02

Similar Documents

Publication Publication Date Title
JP7847880B2 (ja) 組織石灰化を予防または治療するための方法および組成物
US12433854B2 (en) Methods and compositions for preventing or treating calciphylaxis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601